Mastering the Use of Novel Anti-HER2 Treatment Options
Author:
Affiliation:
1. Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy
2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Oncology(nursing),Health Policy,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/OP.21.00216
Reference10 articles.
1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2. Biologic therapy for advanced breast cancer: recent advances and future directions
3. HER2-targeted therapies — a role beyond breast cancer
4. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
5. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases;British Journal of Cancer;2023-08-21
2. Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy;Breast Cancer;2023-08-10
3. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer;Annals of Oncology;2023-08
4. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab;JAMA Oncology;2023-06-01
5. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer;JAMA Oncology;2022-06-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3